The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
Since the first BsAb approval in 2014, the field has rapidly expanded, with solid tumor oncology advancing dynamically. The major focus has been on combining BsAbs with immunotherapy strategies, followed by targeting known oncogenic pathways. The shift toward biotechnology-led innovation underscores the growing therapeutic and financial interest in this field. Optimizing the efficacy and safety of these molecules is key to paving the way for the next era of immune and precision oncology.
Authors
- Mark Gramling
- Aakash Desai (ORCID: https://orcid.org/0000-0002-6604-7712)
- Judith Pérez‐Granado (ORCID: https://orcid.org/0000-0002-4098-3000)
- Chinmay Jani (ORCID: https://orcid.org/0000-0002-6917-5568)
- Rafik ElBeblawy (ORCID: https://orcid.org/0000-0002-9655-7115)
Institutions
- Huntsville Hospital (US)
- University of Miami (US)
- University of Alabama at Birmingham (US)
- Diagnostics Research Group (US)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cam4.71432
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00